SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending heavily following a strong earnings report that highlighted accelerating revenue growth and expanding AI data center momentum. Community members are actively debating the sustainability of this rally, with many investors pointing to bullish long-term growth prospects while others caution against the potential for an overextended valuation following a sharp increase in share price.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as community members spar over whether the stock is ripe for a short squeeze ahead of upcoming federal cannabis rescheduling catalysts or if it is a long-term underperformer plagued by dilution and poor leadership. Despite the divisive sentiment, discourse is heavily focused on whether current levels represent a massive buying opportunity or a signal to avoid the ticker entirely.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing intense parabolic growth and high volatility, fueled by structural memory supply shortages and aggressive demand for AI-focused data center hardware. The community is actively debating whether this movement represents a sustainable long-term re-rating driven by fundamental scarcity or an unsustainable speculative bubble reminiscent of past market excesses.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors rally behind the stock's global expansion strategy and the potential for a short squeeze amid heavy short interest. The community is actively discussing clinical data updates for Anktiva, upcoming earnings reports, and the intensifying scrutiny surrounding the FDA's regulatory environment.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging as part of a broader semiconductor rally fueled by relentless AI-driven memory demand and the critical role of HBM and SSD capacity in data center infrastructure. The community is actively debating the sustainability of this supercycle, with many bulls pointing to low forward valuations compared to growth, while bears urge caution over potentially overextended price action.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is rallying as fresh data indicates its oral Wegovy is significantly outpacing Eli Lilly's recent weight-loss pill launch in prescription volume. The community is increasingly optimistic that this performance shift signals a turn in market momentum, prompting investors to reassess the stock's valuation after a period of intense selling pressure.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after delivering strong earnings and updated guidance that reassured investors about the company's margin recovery and sustained demand for AI infrastructure. The community is actively debating the stock's potential for a massive short squeeze and long-term re-rating, highlighting that the company's current valuation remains significantly undervalued compared to its peers.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is surging following a multi-year colocation deal with AI compute firm Cerebras Systems, fueling intense community debate over its long-term potential versus concerns regarding dilution and volatility. Traders are actively monitoring the stock for momentum-driven gains, with significant discussion focused on whether the infrastructure contract will trigger a major re-rating as the Cerebras IPO approaches.

Wormhole is a cross-chain messaging protocol that enables secure transfers of data or tokens across different blockchain networks. It supports a variety of applications, including DeFi, NFTs, and governance, by allowing data to be moved between blockchains efficiently and securely. Wormhole employs multiple verification methods to ensure the integrity and validity of the data transmitted through its network.

Wormhole

Wormhole is seeing increased engagement as the community reacts to its role in cross-chain interoperability, particularly its integration with institutional partners and major networks like Ripple. Investors are actively debating the tokens potential for a breakout, driven by discussions around strategic reserves, tokenomics updates, and its utility as a bridge across blockchain ecosystems.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

Dogwifhat (WIF) is currently trending as the community debates its future performance, with many participants expressing frustration over persistent sideways trading and frequent price pullbacks despite speculation regarding a potential altcoin season. Discussions frequently center on technical resistance levels, whale accumulation, and comparisons to other meme coins, while the community remains divided between those expecting a significant breakout and those viewing the current price action as a discouraging trend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 70,605 shares, a growth...

Q1 Earnings Estimate for DWTX Issued By Zacks Research

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Equities researchers at Zacks Research issued their Q1 2026 EPS estimates for Dogwood Therapeutics in a research note issued to investors on...

Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday

Dogwood Therapeutics (NASDAQ:DWTX) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-dogwood-therapeutics-inc-stock...

HC Wainwright Issues Positive Forecast for DWTX Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Dogwood Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of...

What is HC Wainwright's Estimate for DWTX FY2030 Earnings?

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Dogwood Therapeutics in a research...

Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1%

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Get Free Report) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 56,171 shares, a...

Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% - Time to Buy?

Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% - Time to Buy...

What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?

<ul class="summary-bullets"><li>Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.</li><li>The company expects to have top-line results from the trial available during the third quarter (Q3) of 2026.&nbsp;</li><li>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026.</li></ul>Dogwood Therapeutics, Inc. (DWTX) said on Monday that patients with chemotherapy induced neuropathic pain (CINP) treated with its painkiller Halneuron demonstrated separation from placebo treated patients in terms of pain improvement over a four-week study. &nbsp;Shares of the company fell 22% at the time of writing and is now poised to log its worst day in over nine months as the update failed to boost investor sentiment.The separation in pain improvement was identified by an independent statistical review committee who reviewed patient treatment data from a mid-stage trial under which 97 patients have completed treatment so far. The company did not <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/Dogwood-Therapeutics-Announces-Positive-Interim-Phase-2b-Clinical-Trial-Results-in-Chemotherapy-Induced-Neuropathic-Pain.html">detail </a>the scale of pain improvement observed in the analysis.The company expects to have top-line results available during the third quarter (Q3) of 2026.Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.<h2 class="st-heading-2">Company Sounds Optimism</h2>According to Dogwood, current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron treatment difference.“Extrapolation of the current Phase 2b study trends has the potential to represent the first statistically significant trial involving CINP patients under FDA chronic pain study guidance,” said CEO Greg Duncan.Halneuron is Dogwood’s lead product candidate and has been granted fast track designation from the FDA for the treatment of CINP. Last month, the company confirmed enrollment of 100 patients in the mid-stage study for Halneuron. The company is targeting enrolling 200 patients in the study in total.“We are hopeful that positive outcomes in this ongoing Phase 2b trial will set the stage for a Phase 3 registration program in CINP, providing a needed therapeutic option for this patient population of cancer survivors,” Chief Medical Officer Michael Gendreau said on Monday.<h2 class="st-heading-2">Limited Operational Runway</h2>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026, before it can announce the results of the ongoing Halneuron trial. &nbsp;The company reported a third quarter basic and diluted net loss per share of $8.20, compared to an analyst estimate of a loss of $1.58 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DWTX fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user now expects the stock to drop as low as $2.<stembedurl>https://www.stocktwits.com/hammerfall43/message/639878419</stembedurl><a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> has nearly doubled this year. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-hits-record-high-as-elon-musk-hints-at-fsd-launch-in-uae-next-month-amid-2018-pay-package-boost/cLeFNmTREMq">Tesla Stock Hits Record High As Elon Musk Hints At FSD Launch In UAE Next Month Amid 2018 Pay Package Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 

Equity

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 


Dogwood Therapeutics, Inc. (DWTX) shares surged 50% in the pre-market session on Monday after the company announced that it has secured a license to develop Serpin Pharma’s intravenous formulation of SP16 to manage cancer-related pain (CRP).The royalty-free, global license will enable the company to develop SP16 for a broad range of chemotherapy-induced neuropathy symptoms as well.In return, Sepin Pharma and its designated affiliates will get 7.31% of the company’s common stock, on a fully diluted basis. This includes 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, it said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Dogwood <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157595/0/en/Dogwood-Therapeutics-Secures-Exclusive-Worldwide-Royalty-Free-License-to-Develop-and-Commercialize-SP16-as-a-Treatment-for-Cancer-Related-Pain-in-an-All-Stock-Transaction-Underscor.html">said</a> that SP16 has demonstrated both anti-inflammatory and neural repair activity. An early-stage trial of the intravenous formulation of SP16, fully funded by the National Cancer Institute, is slated to start patient enrollment in the first half of 2026.“The National Cancer Institute’s funding of the SP16 IV Phase 1b program obviates the need to use our existing capital in the near-term to advance SP16 into clinical development,” CEO Greg Duncan said.The company also noted that SP16 could complement its lead candidate Halneuron, which has demonstrated statistically significant and clinically meaningful pain reductions in general cancer pain, as well as chemotherapy-induced neuropathic pain, respectively.DWTX stock has more than tripled this year and risen by about 79% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug 

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Inc.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

DWTX
Dogwood Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest DWTX News

DWTXDogwood Therapeutics Inc.